论文部分内容阅读
[目的]探讨新辅助化疗联合手术治疗在治疗晚期卵巢癌中的作用和疗效。[方法]选择60例晚期卵巢癌患者作为研究对象,按照治疗方法的不同分为两组,其中30例患者(新辅助化疗组-NACT)采用新辅助化疗,然后进行肿瘤减灭术;另外30例患者(对照组)首先行肿瘤减灭术,再行化疗。[结果]NACT组最佳肿瘤减灭率73.3%,对照组为36.7%,两组比较差异有统计学意义(P﹤0.05);NACT组术中出血量及手术时间较对照组少(短),两组比较差异有统计学意义(P﹤0.05);合并脏器切除率分别为16.7%和20.0%,并发症发生率13.3%和20.0%,组间比较差异无统计学意义(P﹥0.05);新辅助化疗组的中位生存时间(36个月)较先期手术组(27个月)长,1年生存率分别为85.6%和59.2%(P﹤0.05),3年生存率分别为43.6%和45.1%(P﹥0.05)。[结论]对晚期卵巢癌患者进行新辅助化疗有助于提高患者的手术效果和近期生存率,并且具有较好的临床安全性。
[Objective] To explore the effect of neoadjuvant chemotherapy combined with surgical treatment in the treatment of advanced ovarian cancer. [Methods] Sixty patients with advanced ovarian cancer were selected as study subjects and divided into two groups according to the different treatment methods. Thirty patients (neoadjuvant chemotherapy group - NACT) received neoadjuvant chemotherapy and then undergo tumor ablation. Another 30 Patients (control group) first tumor ablation surgery, and then chemotherapy. [Results] The optimal tumor elimination rate was 73.3% in NACT group and 36.7% in control group, with significant difference between the two groups (P <0.05). The NACT group had less (shorter) (P <0.05). The combined organ resection rates were 16.7% and 20.0% respectively. The complication rates were 13.3% and 20.0%, respectively. There was no significant difference between the two groups (P> 0.05) ). The median survival time (36 months) in the neoadjuvant chemotherapy group was longer than that in the primary surgery group (27 months), and the 1-year survival rates were 85.6% and 59.2% (P <0.05) 43.6% and 45.1% (P> 0.05). [Conclusion] Neoadjuvant chemotherapy in patients with advanced ovarian cancer can help to improve the operation effect and short-term survival rate of patients, and has good clinical safety.